Synchronicity

This presentation will share key outcomes, implementation strategies, lessons learned, and future adaptations aimed at reducing barriers and promoting employment equity for TGNC youth. Us Helping Us is also exploring opportunities to expand the program and its impact.

This presentation will outline the current understanding of BV as a dysbiosis, the role of sexual transmission in pathogenesis, and the recent findings of the Australian StepUp* Trial. Practical suggestions will be offered regarding designing and implementing a policy to provide partner therapy for BV in clinical settings in the United States based on the experience at a walk in public Sexual Health Clinic.

Herpes simplex virus (HSV) is one of the most common yet misunderstood sexually transmitted infections, often framed through a deficit-based lens emphasizing stigma, fear, and distress. This presentation issues a strengths-based call to action; reimagining HSV prevention, treatment, and care as opportunities to foster resilience, agency, and self-compassion among patients and providers.

Hepatitis C (HCV) is a curable disease, yet many patients remain untreated due to lack of awareness, outdated perceptions, and barriers to care. This project aimed to identify and link untreated HCV RNA-positive individuals to care within a large, not-for-profit health system in Virginia.

Limited evidence suggests that doxycycline may be comparable to penicillin for the treatment of syphilis, but perhaps less so for latent stages. A total of 655 individuals were included, 539 who were treated with benzathine PCN G (BPG) and 116 treated with doxycycline. For our primary analysis, we included all RPR titers up to 24 months after treatment for all stages of syphilis treated from April 2022 through September 2023.

In 2023, in response to rising syphilis rates and persistent disparities in STI outcomes, we launched a free, community-based STI clinic to expand access to testing and treatment. Prior to this, our services were primarily focused on providing PrEP and HIV care to the LGBT population. In 2024 alone, the clinic served 871 patients—69% of whom identified as ethnic minorities, a population disproportionately impacted by barriers to healthcare access, including PrEP.

Sexually Transmitted Infections (STIs) are a growing public health concern, particularly for women and girls, who experience disproportionately high rates and rising incidence. Barriers such as cost, transportation and geographic access, and appointment availability limit access to timely STI care. For those who do access family planning care, integrating STI testing into comprehensive visits can reduce the need for repeat appointments and improve health and wellbeing.

In recent years, sexually transmitted infections (STI) rates in the United States have risen dramatically, with more than 2.4 million STIs reported in the United States alone (CDC, 2024). STIs can have a profound impact on health, including infertility, neurological and cardiovascular disease, stillbirths, and increased risk of Human Immunodeficiency Virus (HIV). This growing epidemic demands urgent action to enhance the prevention, diagnosis, and treatment of STIs.

Michigan’s hepatitis C (HCV) cases have been on the decline since 2022, due to several coordinated efforts including, eliminating Medicaid restrictions, partnering with a pharmaceutical company to offer low-cost direct acting-antivirals (DAA), to hiring an academic detailer to educate medical students and providers, to creating a hepatitis C disease intervention specialist (DIS) program to link individuals to care.

The Department of Health and Human Services developed a National Strategic Plan to eliminate hepatitis C (HCV) as a public health threat by 2030. However, many barriers to accessing care remain. Pharmacists have increasingly played a role in the treatment of HCV and can support patients and care teams with navigating barriers at multiple steps along the care cascade. The Collaborative Drug Therapy Management (CDTM) model offers a strategy to leverage expertise of embedded pharmacists to improve HCV treatment access and outcomes.

Expanded screening for hepatitis C virus (HCV) infection aims to improve awareness of diagnosis, yet treatment uptake remains suboptimal due to structural, social, and individual-level barriers. People who use drugs face further challenges in accessing HCV treatment due to fragmented care, stigma, and limited support. Strategies to overcome these challenges are needed to improve health equity and achieve HCV elimination. We developed a quality improvement pilot project to integrate expedited DAA initiation, defined as prescribing of DAA during hospital admission.

A translational research project implemented at a Sacramento County sexual health center to reduce barriers to Hepatitis C virus (HCV) treatment. To address elevated prevalence of Hepatitis C in the area, Sacramento County Public Health’s Sexual Health Clinic (SHC) opted to participate in a research project to develop and implement organizational supports and workflows to improve rates of HCV treatment for patients served in this setting.